NASDAQ:YARW Yarrow Bioscience Q1 2025 Earnings Results & Report $14.35 +0.00 (+0.03%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more. Yarrow Bioscience beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$10.00 versus the -$14.50 consensus estimate, while revenue of $200 thousand topped the $50 thousand estimate by $150.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 8, 2025TimeBefore Market OpensConference Call8:00 AM ET Yarrow Bioscience EPS ResultsActual EPS-$10.00Consensus EPS -$14.50Beat/MissBeat by +$4.50One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersYarrow Bioscience Revenue ResultsActual Revenue$200 thousandExpected Revenue$50 thousandBeat/MissBeat by +$150.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Yarrow Bioscience Q1 2025 Earnings FAQ Did Yarrow Bioscience beat earnings estimates for Q1 2025? Yarrow Bioscience (NASDAQ:YARW) reported earnings of -$10.00 per share for Q1 2025, beating the consensus estimate of -$14.50. The report was announced on Thursday, May 8, 2025. What was Yarrow Bioscience's revenue for Q1 2025? Yarrow Bioscience reported revenue of $200 thousand for Q1 2025, against a consensus estimate of $50 thousand. Yarrow Bioscience Earnings HeadlinesYarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 12, 2026 | marketscreener.comMYarrow Reports $9.7 Million Third-Quarter Net Loss and $268.9 Million CashNovember 12, 2026 | quiverquant.comQToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 19 at 1:00 AM | Behind the Markets (Ad)Yarrow Bioscience (NASDAQ:YARW) Stock Rated "Buy" in New Coverage at GuggenheimNovember 9, 2026 | americanbankingnews.comGuggenheim starts Yarrow Bioscience at Buy, citing Graves’ disease potentialNovember 6, 2026 | finance.yahoo.comGuggenheim Initiates Coverage on Yarrow Bioscience With Buy Rating, $60 Price TargetNovember 6, 2026 | marketscreener.comMSee More Yarrow Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Yarrow Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Yarrow Bioscience and other key companies, straight to your email. Email Address About Yarrow BioscienceVYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.View Yarrow Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletTarget Stock Is Up Over 70%—Has the Easy Money Already Been Made?TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off Upcoming Earnings Agilent Technologies (11/23/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.